Who is the CEO of Biocon Ltd.?
- Answer Field
-
Mr. Siddharth Mittal is the current CEO and Managing Director of Biocon Ltd.
BAJAJ BROKING
Biocon Ltd. is one of India’s top biotech firms. It makes and sells pharmaceutical products, biologics, and enzymes. The company works across the full drug development cycle—from research to final production. Biocon uses fermentation-based processes to keep medicines affordable. Its key drugs include Acarbose, Pioglitazone, Repaglinide, and Rosiglitazone for diabetes.
In its biologics segment, it manufactures Insulin, Erythropoietin (EPO), Filgrastim (G-CSF), Streptokinase, and Monoclonal Antibodies. It also makes cholesterol-lowering statins like Lovastatin and Atorvastatin. Biocon’s enzymes are used in industries like food, brewing, textiles, and paper.
Details | Information |
Founded Year | 1978 |
Industry Type | Biotechnology and Pharmaceuticals |
Headquarters | Bengaluru, India |
Key People | Dr. Kiran Mazumdar-Shaw (Chairperson), Siddharth Mittal (CEO & MD) |
Biocon was started in 1978 as a joint venture between Kiran Mazumdar-Shaw and Ireland-based Biocon Biochemicals. It began in a small shed in Bengaluru with just three staff members. Its first exports were papain and isinglass—enzymes used in brewing—sent to the U.S. and Europe.
In 1980, Biocon bought 20 acres of land on Hosur Road for ₹6 lakh and began building what is now its corporate office. This move laid the groundwork for its growth into a global biotech player.
Biocon operates in the global biopharmaceutical sector. It focuses on biosimilars, generics, and research services. The company aims to offer affordable healthcare solutions and serves customers in the U.S., Europe, and other markets. In India, it markets treatments for diabetes, cancer, and autoimmune diseases.
Biocon’s products support key public health needs. It plays a strong role in drug innovation while maintaining accessibility for patients.
Biocon has four core areas: generics, biosimilars, novel biologics, and research services. The generics division makes affordable versions of common drugs. Biosimilars are developed as cost-friendly options to expensive biologics.
Syngene, its research arm, supports pharma companies with pre-clinical and clinical research. Biocon also works on original biologics for chronic conditions. Its full-scale model spans discovery to final manufacturing—making it one of India’s most integrated pharma companies.
Vision: To improve healthcare worldwide through innovative, affordable medicines.
Mission: To become a world-class biotech company by excelling in research, quality manufacturing, clinical research, customer focus, global partnerships, and employee growth.
In 2024, Biocon Biologics crossed $1 billion in annual revenue. Growth came from more market share in the U.S. and expansion into new countries. In 2025, it launched Liraglutide in the UK to treat diabetes and obesity. These steps reflect Biocon’s aim to make life-saving drugs more accessible across the world.
In April 2025, the European Commission approved Biocon Biologics' biosimilars Vevzuo and Evfraxy. These drugs treat bone conditions linked to cancer and giant cell tumour (GCT). The decision followed a positive review from the EU drug authority. This approval strengthens Biocon’s position in regulated markets.
In FY25, Biocon posted revenue of ₹16,470 crore—up 5.4% from ₹15,621 crore in FY24. Net profit rose 10.1% to ₹1,429 crore. Higher sales, especially in international markets and biosimilars, drove growth.
Metric | Value |
Return on Equity (%) | 4.68 |
6.04 | |
Return on Assets (%) | 1.72 |
4.87 | |
Asset Turnover Ratio (x) | 0.27 |
Price to Earnings (x) | 40.49 |
Price to Book (x) | 1.89 |
EV/EBITDA (x) | 13.87 |
EBITDA Margin (%) | 28.66 |
In Q4 FY25, revenue was ₹4,454 crore, up 12% YoY and 15% from the previous quarter. Core EBITDA was ₹1,363 crore with a margin of 31%. Net profit rose to ₹344 crore—up 153%. For the full year, revenue grew 5%, EBITDA rose to ₹4,374 crore, and adjusted net profit increased 30% YoY. R&D spending was ₹859 crore, showing Biocon’s long-term focus on innovation.
Biocon’s share price moved up in recent months. It was ₹354.45 on July 2, 2025, and averaged ₹372.40 recently. While it fell 0.55% in one week, it rose 9.14% over one month and 21.58% over three months. In three years, it returned 5.89%, behind the Nifty 50’s 55.47%.
In the past year, Biocon’s lowest share price was ₹291.00 in October 2024. The highest was ₹404.70 in May 2025. These changes were linked to product approvals and investor confidence in its global business.
As of 10th July 2025, Biocon's market cap stood at ₹49,788.53 crore. Beta values (volatility indicators) were:
1 Month: 0.87
3 Months: 1.37
6 Months: 0.95
1 Year: 0.98
3 Years: 1.08
These show that Biocon’s stock has moderate volatility, especially over short terms.
Strong product mix across biosimilars, generics, and research
Early entry in biologics gives it a market edge
Return ratios are lower than industry leaders
High R&D costs and strict regulations affect margins
Metric | Value |
P/E Ratio (x) | 49.13 |
EPS (TTM) | ₹7.58 |
ROE | 4.68% |
ROCE | 6.04% |
P/B Ratio | 2.37 |
Debt-to-Equity | 0.82 |
Book Value | ₹157.53 |
Face Value | ₹5 |
Dividend Yield | 0.13% |
Biocon has paid dividends over 20 times since 2004. Its most recent was ₹0.50 per share (final), declared on May 8, 2025, with an ex-dividend date of July 4, 2025. Past dividends include regular and special payouts, such as ₹7.50 in 2013.
As of March 2025, the shareholding pattern in the company is as follows:
Shareholder Type | Percentage |
Promoters | 60.63% |
Foreign Investors | 17.88% |
Mutual Funds | 6.72% |
Other Institutions | 3.91% |
Public & Others | 10.86% |
Company | Price | MCap (Cr) | PE | P/B | ROE (%) | 1-Yr Return | Net Profit (Cr) | Sales (Cr) | D/E |
Biocon | 372.40 | 49,788.53 | 49.13 | 2.36 | 4.68 | 2.59% | 1,429 | 15,261 | 0.82 |
Concord Biotech | 1,808.5 | 18,919.84 | 50.73 | 11.89 | 20.57 | 6.59% | 372 | 1,200 | 0.00 |
Sun Pharma Adv | 156.02 | 5,063.19 | – | – | 0.00 | –36.21% | –342 | 71 | –1.19 |
Windlas Biotech | 908.80 | 1,904.78 | 31.40 | 4.04 | 11.99 | 22.75% | 60 | 759 | 0.05 |
Softrak Venture | 1.76 | 79.34 | 176.00 | 0.17 | 0.78 | 19.73% | 0 | 2 | 0.00 |
Biocon is among the largest Indian biotech companies by market value. With almost ₹50,000 crore in market cap, it has built strong expertise in biosimilars. It also exports to regulated markets like the U.S. and EU. Its leadership in insulin and oncology biosimilars supports its global reach.
Biocon is expanding across biosimilars, generics, and novel biologics. Its experience in fermentation and green chemistry gives it an edge. With the Viatris deal, it added scale and access in global markets. Biocon is also exploring growth in the GLP-1 diabetes and obesity drug category.
Approval delays and pricing pressure affect revenue in global markets. The biosimilar space is seeing more players, which affects margins. R&D carries high risk—any failed trials can hit product pipelines. Currency swings and policy shifts in export markets add more risk.
You can track Biocon’s share price live on NSE and BSE. Most financial platforms, apps, and brokerage websites show real-time charts and trade data. Visit www.biocon.com for earnings updates, regulatory filings, and investor presentations.
Share this article:
No Data Found
Mr. Siddharth Mittal is the current CEO and Managing Director of Biocon Ltd.
Biocon Ltd. is a publicly listed private company. It is not owned or managed by the government.
Biocon is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) under the symbol BIOCON.
Open a demat account with a registered broker and place buy orders for “BIOCON” on NSE or BSE.
The face value of each Biocon share is ₹5.
Yes, Biocon has previously issued bonuses and has undergone share splits. Investors can check historical corporate actions in the IR section.
The official website is www.biocon.com. Investor queries can be directed through the contact forms on the Investor Relations page.
Yes, Biocon publishes annual reports, earnings presentations, and ESG disclosures on its website under the Investor Relations tab.
Biocon is part of indices such as BSE 200 and S&P BSE Healthcare, but not the Nifty 50.
Biocon develops affordable biopharma drugs and biosimilars for chronic diseases. It operates across the full drug lifecycle—from research to commercialisation—serving both domestic and international markets.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading